Evidence map›Paper›PMID 33925081›Full record

ArticleInternational journal of molecular sciences2021

In Vitro Cytotoxicity of Trastuzumab (Tz) and Se-Trastuzumab (Se-Tz) against the Her/2 Breast Cancer Cell Lines JIMT-1 and BT-474.

Priyanka Bapat, Debalina Goswami Sewell, Mallory Boylan, Arun K Sharma, Julian E Spallholz

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Priyanka BapatNutritional Sciences, College of Human Sciences, Texas Tech University, Lubbock, TX 79409, USA.
Debalina Goswami SewellNutritional Sciences, College of Human Sciences, Texas Tech University, Lubbock, TX 79409, USA.
Mallory BoylanNutritional Sciences, College of Human Sciences, Texas Tech University, Lubbock, TX 79409, USA.
Arun K SharmaDepartment of Pharmacology, Penn State Cancer Institute, CH72, Penn State College of Medicine, 500 University Drive, Hershey, PA 17033, USA.
Julian E SpallholzNutritional Sciences, College of Human Sciences, Texas Tech University, Lubbock, TX 79409, USA.
Texas Tech University · USPenn State Milton S. Hershey Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Her/2+ breast cancer accounts for ~25% mortality in women and overexpression of Her/2 leads to cell growth and tumor progression. Trastuzumab (Tz) with Taxane is the preferred treatment for Her/2+ patients. However, Tz responsive patients often develop resistance to Tz treatment. Herein, redox selenides (RSe-) were covalently linked to Tz using a selenium (Se)-modified Bolton-Hunter Reagent forming Seleno-Trastuzumab (Se-Tz; ~25 µgSe/mg). Se-Tz was compared to Tz and sodium selenite to assess the viability of JIMT-1 and BT-474 cells. Comparative cell viability was examined by microscopy and assessed by fluorometric/enzymatic assays. Se-Tz and selenite redox cycle producing superoxide (O

Indexed as

Antineoplastic Agents, ImmunologicalApoptosisBreast NeoplasmsCaspase 3Cell Line, TumorCell SurvivalDrug Resistance, NeoplasmErb-b2 Receptor Tyrosine KinasesFemaleHumansMicroscopy, Electron, ScanningOrganoselenium CompoundsOxidation-ReductionSeleniumSuperoxidesTrastuzumabAntineoplastic Agents, ImmunologicalCASP3 protein, humanCaspase 3ERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesOrganoselenium CompoundsSeleniumSuperoxidesTrastuzumabantibody drug conjugate (ADC)epidermal growth factor receptor (EGFR)Herceptin®human epidermal growth factor receptor 2 (Her/2)Kadcyla® (T-DM-1)monoclonal antibody (mab)reduced glutathione (GSH)selenium (Se)superoxide (O2•−)Trastuzumab (Tz)

Identifiers

PMID33925081
PMCPMC8124313
OpenAlexW3158344027

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.